Introduction
============

Cervical cancer is one of the most common types of gynecological malignancies around the world, which includes uncontrolled cell division and tissue of the female uterine cervix. In less developed countries, cervical cancer among females is the leading cause of cancer death. There were an estimated 527,600 new cervical cancer cases and 265,700 deaths worldwide in 2012[@B1]. It is the second most commonly diagnosed cancer and the third leading cause of cancer death among females in less developed countries[@B1]. Nearly 90% of cervical cancer deaths occurred in developing countries [@B1]. More advances in the treatment methods have been improved in less developed countries.

Traditionally, lymph node status is considered as one of the most important clinical parameters in the treatment determination and prognosis for cervical cancer[@B2]. The number of positive lymph node (PLNs) is the main factor affecting the 5-year overall survival rate of cervical cancer patients[@B3], [@B4]. The current International Federation of Gynecology and Obstetrics(FIGO) staging system does not assess lymph node status, though this feature is a prognostic factor and the 7th edition of the American Joint Committee on Cancer(AJCC)/Union for International Cancer Control(UICC) staging system only classifies the lymph nodes as N0 (negative) or N1 (positive)[@B5], [@B6].Currently, lymph node status is always based on PLN regardless of the number of resected lymph node (RLNs) in cervical cancer patients[@B7], [@B8]. In early stage cervical carcinoma, the 5-year overall survival rate of patients with lymph node positive was reported to be around 50%, while that of non-lymph node metastasis was more than 90%[@B9]. However, in the clinical practice clinicians demonstrate that lymph node status might not sufficiently be reflected by the number of the positive lymph nodes.

Recently, the lymph node ratio (LNR) that is the ratio of PLNs to RLNs, and log of odds between PLNs and the number of negative lymph node (LODDS) have emerged as alternative predictive factors for outcomes and showed superiority to lymph node status-based assessment in pancreatic cancer[@B10], [@B11], oral cancer [@B12], [@B13], non-small cell lung cancer [@B13],colorectal cancer[@B14], ovarian cancer[@B15], breast cancer[@B16]. LNR was also studied in ovarian cancer and found to be superior to both PLN and RLN in predicting survival [@B17], [@B18]. LODDS is defined as log ((the number of PLNs +0.05)/ (the number of negative nodes +0.05)). While this parameter has been validated in predicting survival for breast cancer, its utility in cervical cancer still remain unclear [@B19]-[@B21].

In this study, we hypothesized that LODDS might be an important prognostic predictor and has better predictive performance than LNR in cervical cancer patients. In addition, a nomogram incorporating LODDS may be superior in this respect to the currently-utilized FIGO score staging system.

Material and Methods
====================

Data source and eligibility criteria
------------------------------------

We identified cervical cancer cases from the SEER program of the National Cancer Institute (<http://seer.cancer.gov/>). Inclusion criterion is that all patients who were pathologically confirmed with cervical cancer from the SEER database from 2004 to 2014. Exclusion criteria are as follows: unknown age of diagnosis; uncertain race; unknown marriage status; undetermined grade; unknown stage; unspecified neoplasms; unknown tumor size; unknown or incomplete lymph node status. Finally, a total of 8202 cervical cancer patients were included in this study. These patients were divided into training and validation cohorts based on consecutive age of diagnosis (training cohort between 2004 and 2008, *N*=3603; validation cohort between 2009 and 2014, *N*=4599). In our study, \'married\' was recorded as married and unmarried but having domestic partner; single was recorded as \'single\'; separated, divorced and widowed were classified as "others". Except squamous cell neoplasm and adenomas and adenocarcinomas, other histology types were recorded as "other".

Statistical analysis
--------------------

Categorical measurements were described as count and percentage, while continuous measurements were presented as mean and range. The chi-square was used to compare the categorical measurements, while *t* test for continuous ones. The optimal cutoff point for LODDS was determined by ROC curve in training cohort with the package of survivalROC in R. The nomogram was built with potential risk factors (*P* \<0.05) based on multivariate Cox analysis in the training cohort with the package of *rms*in in R. The predictive performance of the nomogram was measured by concordance index (C-index) and it compared nomogram-predicted survival probability with observed Kaplan survival probability. C-index comparisons between the nomogram and FIGO staging system were performed using thercorrp.cens package in *Hmisc* in R. The larger the C-index, the more accurate for the prognostic prediction. The predictive performance was validated by an independent external cohort. All statistical analyses were performed in R version 3.3.3 (<http://www.r-project.org/>).

Results
=======

Patients Characteristics
------------------------

In the training cohort, a total of 3603 cervical cancer patients between 2004 and 2008 were involved. A total of 4599 consecutive patients between 2009 and 2014 were involved in the validation cohort. The demographic and clinicopathologic characteristics of patients in the training and validation cohorts were listed in Table [1](#T1){ref-type="table"}.

Optimal Cutoff for LODDS in Predicting OS
-----------------------------------------

In order to facilitate the application of LODDS in clinical practice, we dichotomized LODDS into high LODDS and low LODDS based on the optimal cutoff from ROC curve. In our training cohort, the optimal cutoff was -4.394. We further validated the predicting performance of binary LODDS in an independent external dataset.

Independent Prognostic Factors of OS in the Training Cohort
-----------------------------------------------------------

The results of the univariate and multivariate analysis were listed in Table [2](#T2){ref-type="table"}. Univariate analyses demonstrated that age at diagnosis, race, marital status, grade, stage, histology, PLN, LNR, RLN and LODDS were associated with OS. Multivariate analysis demonstrated that age at diagnosis, race, marital status, grade, stage, histology, tumor size and LODDS were independent risk factors for OS (Table [2](#T2){ref-type="table"}).

Prognostic Nomogram for OS
--------------------------

The prognostic nomogram that integrated all significant independent factors from multivariate analysis for OS in the training cohort was shown in Figure [1](#F1){ref-type="fig"}. The C-index of prognostic nomogram for OS prediction was 0.749 (95%CI, 0.731 to 0.767) in the training cohort and 0.786 (95%CI, 0.746 to 0.808) in the validation cohort. The calibration plot for the probability of survival at 3 or 5-year after surgery showed an optimal agreement between the prediction by nomogram and actual observation in the training cohort (Figure [2](#F2){ref-type="fig"}A and [2](#F2){ref-type="fig"}B) and in the validation cohort (Figure [2](#F2){ref-type="fig"}C and [2](#F2){ref-type="fig"}D), respectively.

Comparison with FIGO scoring system
-----------------------------------

The C-indices for FIGO staging and nomogram were 0.633 (95%CI: 0.615 to 0.651) and 0.749 (95%CI: 0.731 to 0.767) in the training cohort (*P*\<0.01), respectively, and 0.685 (95%CI: 0.660 to 0.710) and 0.786 (95%CI, 0.746 to 0.808) in the validation cohort (*P*\<0.01), respectively.

Discussion
==========

The present study suggested that age at diagnosis, race, grade, FIGO stage, histology, tumor size, LODDS were independent prognostic factors of OS in cervical cancer after surgery. The nomogram was created based on these prognostic factors and was used to predict the 3-year and 5-year OS after surgery in the cervical cancer patients. In the training and validation cohorts, the nomogram showed better predictive performance than the FIGO staging system for OS.

As far as we know, the nomogram has been applied to predict the survival status of various cancers [@B22]-[@B24]. Since the nomogram quantifies risk by combining and illustrating the relative importance of various prognostic factors and has been used in clinical oncology assessment. Although LODDS has been described as a predictor of cervical cancer, the nomograms with LODDS to predict the prognosis of cervical cancer after surgery has not been described[@B25].

To our knowledge, PLNs have been reported as a prognostic factor for cervical cancer. However, PLNs, part of RLNs, do not fully reflect the disease state in all situations[@B26]. Therefore, it is important to take simultaneously PLNs and the number of negative lymph nodes consideration for predicting the prongosis of cervical cancer. LODDS is an intuitive indicator that is reflective of both PLNs and the number of negative lymph nodes and it has been used to predict the prognosis of survival in other cancers. From out study, it is found that LODDS is an independent prognostic factor of cervical cancer and we take -4.394 as the optimal cutoff point for the LODDS based on ROC curve analysis from the training cohort. Meanwhile, we fully verify the nomogram accuracy with this optimal cutoff in an independent external cohort. From the created nomogram, females younger than 30 years old have higher score than older than 30 but younger than 50 years old, though this former group have no significance.

FIGO staging is the most common staging system for cervical cancer, so we compared C-index of the nomogram with that of FIGO stage and found that the C-index for the nomogram to predict OS were 0.749, 0.786 respectively in the training cohort and the validation cohort and higher than FIGO. In addition, the calibration plots represented that a perfect match between the nomogram predicted probability and the actual probability calculated by Kaplan-Meier analysis, especially for 3-year survival. These results showed that our nomogram could be used in practical work with less bias and better accuracy. In addition, we used the nomogram to calculate 3-year and 5-year survival rate individually so that the nomogram can help clinical make a more reasonable follow-up plan.

There are still several limitations that must be considered though the nomogram model demonstrated good accuracy for predicting OS. Firstly, the C-index of the nomogram is good but not excellent. Secondly, there are many factors may influence that may influence prognosis of postoperative cervical cancer patients so that further research should be carried to improve the nomogram.

In summary, our study demonstrated that age at diagnosis, race, grade, FIGO stage, histology, tumor size, LODDS are independent prognostic factors of OS in cervical cancer. In addition, we created the nomogram based on LODDS to predict estimate 3- and 5-year OS among postoperative cervical cancer patients which had good accuracy.
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###### 

Demographic and clinicopathological characteristics of patients with cervical cancer between 2004 and 2014 in SEER database

  ------------------------------------------------------------------------------------------------------------
  Demographic or Characteristics   All subjects\     Training\        Validation cohort (N=4599)   *P* value
                                   (N=8202)          cohort\                                       
                                                     (N=3603)                                      
  -------------------------------- ----------------- ---------------- ---------------------------- -----------
  **Age at diagnosis (year)**                        0.002                                         

  x\<30                            521(6.35)         228(6.33)        293(6.37)                    

  30≤x\<50                         4757(58.00)       2169(60.20)      2588(56.27)                  

  50≤x\<70                         2442(29.77)       996(27.64)       1446(31.44)                  

  x≥70                             482(5.88)         210(5.83)        272(5.91)                    

  **Race**                                                                                         0.016

  White                            6554(79.91)       2879(79.91)      3675(79.91)                  

  Black                            687(8.38)         331(9.19)        356(7.74)                    

  Asian                            824(10.05)        344(9.55)        480(10.44)                   

  Others                           137(1.67)         49(1.36)         88(1.91)                     

  **Marital Status**                                                  0.054                        

  Single                           2194(26.75)       917(25.45)       1277(27.77)                  

  Married                          4417(53.85)       1984(55.07)      2433(52.90)                  

  Other                            1591(19.40)       702(19.48)       889(19.33)                   

  **Grade**                                                                                        \<0.001

  High                             1250(15.24)       496(13.77)       754(16.39)                   

  Medium                           3602(43.92)       1546(42.91)      2056(44.71)                  

  Low                              3110(37.92)       1459(40.49)      1651(35.90)                  

  Undifferentiated                 240(2.93)         102(2.83)        138(3.00)                    

  **Stage**                                                                                        0.874

  I                                6704(81.74)       2953(81.96)      3751(81.56)                  

  II                               1005(12.25)       430(11.93)       575(12.50)                   

  III                              170(2.07)         75(2.08)         95(2.07)                     

  IV                               323(3.94)         145(4.02)        178(3.87)                    

  **Histology**                                                                                    0.015

  squamous cell neoplams           4557(55.56)       2060(57.17)      2497(54.29)                  

  adenomas and adenocarcinomas     2673(32.59)       1115(30.95)      1558(33.88)                  

  Other                            972(11.85)        428(11.88)       544(11.83)                   

  **Tumor size**(**cm**)                                              0.042                        

  x\<4                             6030(73.52)       2608(0.7238)     3422(0.7441)                 

  x≥4                              2172(26.48)       995(0.2762)      1177(0.2559)                 

  **LODDS\***                                                                                      0.032

  mean(range)                      -4.870\           -4.818\          -4.910\                      
                                   (-7.496 -7.245)   (-7.496-5.638)   (-7.496-7.245)               

  **RLNs\***                                                                                       0.113

  mean(range)                      19.287(1-90)      19.517(1-90)     19.107(1-90)                 

  **PLNs\***                                                                                       0.304

  mean(range)                      0.618(0-70)       0.644(0-37)      0.597(0-70)                  

  **LNR\***                                                                                        0.099

  mean(range)                      0.044(0-1)        0.047(0-1)       0.042(0-1)                   
  ------------------------------------------------------------------------------------------------------------

\*LODDS: log((the number of PLNs +0.05)/ (the number of negative nodes +0.05)); RLNs: the number of resected lymph node; PLNs: the number of positive lymph node; LNR: the lymph node ratio.

###### 

Univariate analysis and multivariate analysis in the training cohort

  Variables                      Univariate Analysis             Multivariate Analysis                        
  ------------------------------ --------------------- --------- ----------------------- -------------------- ---------
  **Age at diagnosis**                                                                                        
  x\<30                          reference                                               reference            
  30≤x\<50                       0.868(0.620-1.214)    0.407                             0.945(0.672-1.329)   0.744
  50≤x\<70                       1.594(1.134-2.239)    0.007                             1.321(0.931-1.874)   0.119
  x≥70                           3.490(2.408-5.058)    \<0.001                           2.941(1.987-4.354)   \<0.001
  **Race**                                                                                                    
  White                          reference                                               reference            
  Black                          0.899(0.691-1.170)    0.021                             1.347(1.070-1.696)   0.011
  Asian                          1.305(1.042-1.635)    0.049                             0.791(0.606-1.032)   0.083
  Others                         1.134(0.625-2.060)    0.679                             0.879(0.483-1.602)   0.674
  **Marital status**                                                                                          
  Single                         reference                                               reference            
  Married                        0.945(0.788-1.133)    0.544                             1.053(0.873-1.271)   0.590
  Other                          1.621(1.324-1.984)    \<0.001                           1.402(1.126-1.746)   0.003
  **Grade**                                                                                                   
  High                           reference                                               reference            
  Medium                         1.709(1.274-2.294)    \<0.001                           1.358(1.001-1.842)   0.049
  Low                            2.668(2.001-3.556)    \<0.001                           1.637(1.202-2.229)   0.002
  Undifferentiated               3.646(2.351-5.655)    \<0.001                           1.604(1.017-2.532)   0.042
  **Stage**                                                                                                   
  I                              reference                                               reference            
  II                             2.711(2.259-3.255)    \<0.001                           1.562(1.283-1.901)   \<0.001
  III                            4.769(3.450-6.591)    \<0.001                           2.608(1.859-3.57)    \<0.001
  IV                             6.721(5.361-8.425)    \<0.001                           3.557(2.767-4.571)   \<0.001
  **Histology**                                                                                               
  squamous cell neoplams         reference                                               reference            
  adenomas and adenocarcinomas   0.697(0.594-0.833)    \<0.001                           0.962(0.794-1.164)   0.690
  Other                          1.695(1.400-2.053)    \<0.001                           1.682(1.381-2.049)   \<0.001
  **Tumor size**(**cm**)                                                                                      
  x\<4                           reference                       reference                                    
  x≥4                            2.734(2.356-3.160)    \<0.001                           1.706(1.454-2.000)   \<0.001
  **RLN**                        0.957(0.980-0.993)    \<0.001                           0.995(0.989-1.001)   0.089
  **LNR**                        15.75(11.85-20.90)    \<0.001                                                
  **PLN**                        1.131(1.115-1.147)    \<0.001                                                
  **LODDS**                                                                                                   
  \<-4.394                       reference                                               reference            
  ≥-4.394                        2.943(2.547-3.402)    \<0.001                           1.809(1.541-2.125)   \<0.001
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